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Background: To determine if a standardized, non-xenogenic, reduced manipulation cultivation and surgical
transplantation of limbal stem cell grafts is a safe and effective treatment option for patients with total and partial
limbal stem cell deficiency.
Methods: In vitro cellular outgrowth and phenotype of the limbal epithelial cell and composite grafts were validated
using a new protocol. Patients received either autologous (n = 15) or allogenic (n = 3) explants cultured using a
standardized protocol free from xenogenic products. The resulting grafts were transplanted using a reduced
manipulation surgical technique.
Results: The majority of cells (>50%) displayed a progenitor phenotype typified by positive immunofluorescence
for ΔNp63, CK14 and ABCG2 and low immunofluorescence for CK3/12 and desmoglein 3 proteins. The surgical
protocol was designed to minimize manipulation and the graft itself was secured without sutures. The transplant
recipients were followed for a mean of 24 months. Twelve of the 18 transplant recipients were graded as anatomically
successful (67%), based on the defined success parameters. There was a significant reduction in corneal
neovascularization, which was accompanied by an improvement in pain though not photophobia or central
corneal opacity post transplant. The transplantation protocol showed no measureable effect on visual acuity.
Conclusion: We conclude that this standardized culture system and surgical approach is safe and effective in
reducing corneal neovascularization. The technique is free from animal contaminants and maintains a large
proportion of progenitor cells. Although this technique did not improve visual function, restoring a functional
epithelial cell layer and reducing corneal neovascularization provides an improved platform for a penetrating
keratoplasty to ultimately improve visual function.
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Limbal stem cell deficiency (LSCD) can result from a range
of pathologies including ocular cicatricial pemphigoid,
Stevens Johnson syndrome, aniridia, multiple surgeries
and trauma [1]. The limbus is depleted of the resident
epithelial stem cells permitting a vascular conjunctival
membrane to grow over the cornea resulting in scarring,
poor vision, pain and photophobia. These patients are a
high-risk group for treatment with vision restoring therap-
ies such as penetrating keratoplasty (PK) [2]. Limbal stem
cell deficiency is an orphan pathology, which prior to 1998
had limited therapeutic options. Transplantation may be
performed either by directly implanting a kerato-limbal
graft or by harvesting a biopsy, expanding the cells by tissue
culture and then transplanting the graft [3]. The advantage
of the latter is that it requires a smaller volume of donor
tissue, reducing the risk of LSCD in the donor eye [4].
The emergence of clinical trial data supporting the
benefit of limbal stem cell transplantation has led to its
more widespread use [5-14], and as transplantation
procedures increase, the need for optimization and
standardization of the technique comes to the fore. In
this paper we present the results of a clinical trial that
contains data on the additional steps we have taken in
seeking a more ideal transplantation protocol.
Our primary aims were to standardize the limbal stem cell
protocol where possible, remove any animal derived product
and to apply a minimal manipulation surgical protocol in
order to improve clinical outcomes. An alternative medium
was assessed, a means of amnion membrane fixation used
and the surgical procedure optimized to simplify trans-
plantation and reduce manipulation and suture influence.
Post-operative outcome assessments included quantitative
measurements of corneal neovascularization, opacity and
visual acuity and subjective reports of pain and photopho-
bia. Clinical examination was performed to assess graft
integrity and anatomy. All of these factors were assessed
to determine the safety and efficacy of the protocol.
Materials and methods
The study was approved by the Antwerp University
Hospital Ethical Committee (approval number: EC7/
28/153; EudraCT no 2008-001543-19) and followed the
tenets of the Declaration of Helsinki. Written informed
consent was obtained from all participants after explan-
ation of the procedure and possible side effects. Patients
that were pregnant or lactating, suffering from severe
psychological disorders, or had active inflammation of
the eye were excluded from the study.
Animal-product free culture protocol validation
Progenitor cell targeted (PCT) CNT-20 media (CellnTec,
Switzerland) supplemented with 1% human type AB serum
was compared with supplemental hormonal epithelialmedium (SHEM) consisting of DMEM/F12 supplemented
with 5% fetal bovine serum (FBS), 50 μg/ml gentamycin,
1.25 μg/ml amphotericin B, 5 μg/ml insulin-transferrin-
selenium growth supplement (all from Gibco, Invitrogen,
Belgium), 5% DMSO, 30 ng/ml cholera toxin, 0.5 μg/ml
hydrocortisone (all from Sigma Aldrich, Diegem, Belgium)
and 2 ng/ml epidermal growth factor (Millipore, MA, USA).
Human corneo-scleral tissue (n = 5) was obtained from
the cornea tissue bank (UZA, Belgium) and two limbal
explants were obtained from each eye (total n = 10), Limbal
stem cell amnion grafts were generated using methods
described previously [15]. The membranes were pre-
pared on interlockable plastic rings as described below.
Briefly, the explants were cultured for 14 days at the
air liquid interface in either CNT-20 (n = 5) or SHEM
(n = 5) after which they were fixed in 4% paraformalde-
hyde for one hour. Tissue whole mounts were prepared
and stained with primary antibodies, used in accord-
ance with the manufacturers’ instructions, against collagen
IV (Abcam: ab6586, dilution 1/100), integrin α6 (Abcam:
ab20142, 1/50), collagen II (Abcam: ab34712, 1/100),
laminin (Abcam: ab11575, 1/25), connexin 43 (Millipore:
MAB3068, 1/50), ΔNp63 (Santa Cruz Biotechnology:
sc-8609, 1/300). All samples were observed and photo-
graphed using a laser scanning confocal microscope
(LSM510, Carl Zeiss).
Freshly isolated limbal epithelial cell (LEC) phenotypic
profiles were compared to that of LECs grown to con-
fluence in CNT-20 media with respect to expression of
hematopoietic markers (CD14, CD45), markers of stem-
ness (CD73), secretory markers (CD227/MUC1), fibro-
blast markers (CD10, CD90) and adhesion molecules
(CD29/integtin β1, CD166/ALCAM) using flow cytometry
(Figure 1). LEC profiles were also compared with epithelial
cells harvested from cadaveric corneas. Results were ana-
lyzed in FlowJo version 8.8.4 for Macintosh and statistical
analysis performed using GraphPad Prism 5.
Diagnosis and classification of limbal stem cell deficiency
The diagnosis of LSCD was made clinically. The pres-
ence of conjunctivalizaton (one or more signs: corneal
vascularization, corneal epithelial defects, scarring, late
fluorescein staining) with the absence of normal limbal
architecture (limbal palisades of Vogt) was indicative of
LSCD. Ocular surface photographs were taken to docu-
ment the corneal neovascularization, opacity and epithe-
lial defects. Impression cytology was performed as an
adjunct to confirm the diagnosis (data not shown) [16].
Visual acuity was recorded using the ETDRS chart and
where patients had visual impairments of counting fingers,
hand movements a numerical conversion was performed
as described [17]. Light perception was registered numer-
ically as a visual acuity of 0. Pain was recorded using a
numerical pain scale (0–10, 0 corresponding to no pain
Figure 1 Flow cytometry profiles of limbal epithelial cells grown in CNT-20 medium. LEC cytometry profiles at isolation and at confluence
(A), phenotypic profile of LECs at confluence (B) (***p < 0.001).
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verbal descriptor scale) [18]. Photophobia was recorded
similarly using a 4 point scale (0 = nil photophobia, 1 =mild,
2 =moderate and 3 = severe photophobia). Schirmer’s test 1
was performed to ensure the presence of an adequate tear
film. Patient with values <5 mm in 5 minutes required
punctal plugs prior to surgery. The complete absence
(360˚) of limbal architecture with conjunctivalization
was termed total limbal stem cell deficiency. The in-
volvement of fewer clock hours was considered to be
partial deficiency.
Limbal biopsy
The limbal biopsy was harvested under local anesthesia
from the contralateral eye in cases of unilateral disease
(n = 15) and from a HLA (>50%) matched living related
donor in bilateral disease (n = 2) and one unmatchedcadaveric donor (n = 1). For the living related donors, a
three loci match of at least 50% was favored taking into
account HLA-A, HLA-B and HLA-DR. A superficial
area of 1 mm by 2 mm was harvested from either the
superior or inferior limbus using a 45˚ diamond blade to
delineate the biopsy and a crescent knife to tunnel to a
depth of approximately 100 microns. The biopsy was
placed in PCT CnT-20 medium and transported to the
laboratory where it was rinsed with culture medium
containing antibiotics.
Standardized generation of limbo-amnion composite graft
The human amnion membrane (HAM) was standardized
by removal of a thick, hydrophilic, spongy layer and amni-
otic epithelial cells as previously reported [15,19,20]. The
resulting membrane was secured with two interlockable
plastic amnion rings (35 mm Lumox cultureware, Greiner
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upwards. The interlockable ring design ensures that the
HAM remains oriented and smooth from culture to
transplantation. The limbal biopsy was placed on the
membrane and cultured in corneal progenitor cell tar-
geted CnT-20 medium supplemented with 1% human
blood type AB serum (Sigma Aldrich, Germany) at the
air liquid interface at 37˚C and 5% CO2. Limbal explants
were cultured for 14 days under these conditions with the
medium changed every 2 to 3 days. The culture was moni-
tored for cell morphology and the diameter of the cell out-
growth recorded. An outgrowth of >8 mm in diameter
with limbal epithelial cell morphology and negative run-
ning test results for microbes (aerobes, anaerobes, fungi
and mycobacterium) allowed release of the composite
graft for transplantation.
Immunofluorescent labeling of composite grafts
Cultured graft whole mounts were labeled with anti-
CK14 (Chemicon: CBL197; dilution 1/50), anti-BCRP/
ABCG2 (Calbiochem: OP191; 1/50) and anti-p63 anti-
body (Thermo Scientific: rb-9424-R7;1:1) to determine
the presence of corneal epithelial progenitor cells. Anti-
desmoglein 3 (Abcam, AB14446; 1/200) and anti-CK 3/
12 (Chemicon:CBL218; 1/50) were used to establish the
presence of terminally differentiated corneal epithelial
cells. The presence of vascular endothelial growth factor
receptors VEGF-R1 (Epitomics: 1303–1, 1/250) and
VEGF R3/FLT (Santa Cruz: Sc-28297, 1/50) was also in-
vestigated (data not shown). Normal human corneal
cross sections were routinely used as negative controls
where the primary antibodies were omitted from the
staining protocol. The samples were observed and photo-
graphed under a Laser Scanning Confocal Microscope
LSM510 Duphoton (Carl Zeiss).
Surgical technique: cultivated limbal stem cell
transplantation
The compostie grafts were transplanted using a minimal
manipulation technique. [15] Briefly, a 360˚ conjunctival
periotomy was performed followed by dissection of the
fibrovascular pannus. In cases of partial limbal stem cell
deficiency, only the localized pannus was dissected be-
yond the limbus. Fibrin glue (TissueCol®) was applied to
the surface of the cornea and the graft, secured within
the plastic rings, was positioned. This was done by
grasping the plastic rings and lowering the construct
onto the denuded cornea, without touching the graft
itself. Once the glue had set, the graft was cut out of the
rings just beyond the limbs. A secondary HAM was
placed over the graft (spongy layer facing up), tucked
under the free edges of the conjunctiva and secured
using four 10–0 nylon sutures. This membrane served
as a temporary membrane patch. A bandage contact lenswas applied and left in place until the removal of all
sutures one-week post transplant.
Post-operative medication
Autologous transplant recipients were prescribed the
following regimen: 0.3% ofloxacin drops 4×/day, prednis-
olone drops 8×/day, autologous serum drops 8×/day
continued for one month and then gradually tapered.
Allogenic transplant recipients were also prescribed oral
cyclosporine A 2×125 mg/day (commenced 1 week prior
to transplantation maintaining blood trough levels at
approx 100 to 150 ng/ml), solu medrol 125 mg IV peri
operatively, continued for 3 days post op then switched
to methylprednisolone 1 mg/kg/day. Systemic immuno-
suppression was tapered and discontinued at one-year
post transplantation.
Definition of successful outcome parameters
Success was judged based on two factors: 1. Reversion to
a persistent intact epithelium was deemed an ‘anatomical
success’ and 2. A functional improvement in pain, photo-
phobia and visual acuity was termed ‘functional success’.
Quantifying corneal neovascularization and opacity
Ocular surface photographs were analyzed using our
previously published technique for quantifying corneal
neovascularization [21]. The degree of corneal opacifica-
tion was assessed by taking slit-lamp photographs and
analyzing the images within Matlab. A circular region in
the central 25% of the cornea was examined. Corneal
backscatter in severe opacification is mostly in the blue-
white hue and it was elected to use the average intensity
of the light in the blue channel for quantifying central
corneal opacity.
Statistics
The efficacy of cultivated limbal epithelial transplant-
ation was examined by comparing the outcome pa-
rameters (corneal neovascularization, corneal opacity,
pain and photophobia) pre and post transplantation by
Wilcoxon signed rank tests. The overall success per-
centage together with a 95% confidence interval was
calculated. Success outcomes were based on the total
group. Post-operative improvements were assessed for
the entire group and also in the subgroup of patients
in whom the grafts achieved stability and were deemed
anatomical success. Visual acuity was compared pre
and post transplantation with a sign test. The influ-
ence of gender and etiology on the success rate of
LSCD was assessed with the Fischer Exact Test. In
addition, a linear regression analysis was performed to
examine the effect of age, gender and etiology on the
outcome parameters. All analyses were performed using
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significance level of 0.05.
Results
Animal product-free culture validation
The initial media validation experiments confirmed cel-
lularization of the HAM with cobblestone-like appear-
ance of LECs in both SHEM and progenitor cell targeted
CNT-20 medium. Both CNT-20 and SHEM showed a
similar expression for ΔNp63 and extracellular matrix
proteins: collagen IV, laminin and connexin 43 (Figure 2).
The expression of integrin α6 was positive though
reduced in the CNT-20 cultures when compared with
SHEM cultures. In the CNT-20 cultures, collagen II was
highly expressed in the cell membranes with weak
cytoplasmic expression, but minimal expression was
observed in the SHEM cultures. LECs cultivated in pro-
genitor cell targeted CNT-20 medium were negative for
the hematopoietic markers: CD14, CD45 and fibroblast
markers: CD10, CD90 while positive for stemness: CD73,
secretory CD227, adhesion molecules: CD29, CD166.
Moreover, cells cultivated to confluence in CNT-20 dis-
played a significantly higher expression of stem cell
marker CD73 (p > 0.001) and adhesion molecule CD166
(p > 0.001) when compared with freshly isolated epithelial
cells from donor cadaveric corneas (Figure 1). Initial
experiments displayed adequate expansion of LECs in
CNT-20 serum-free medium on plastic cultureware but
this could not be replicated with LECs on HAM (data
not shown).
Pre-operative assessment and recruitment
Eighteen patients with LSCD were enrolled in the clinical
trial, 11 males and 7 females with a mean age of 40.6 years
(range 6–79). Sixteen patients had unilateral and 2 had
bilateral disease. Out of the 18 patients enrolled, 15 were
diagnosed with total and 3 with partial limbal stem cell
deficiency. The three partial limbal stem cell deficient par-
ticipants are shown (Figure 3A-C) with representative im-
ages of the total LSCD patients (Figure 3D-F). The most
common cause for the limbal stem cell deficiency was
chemical burn (n = 7). Other causes are listed in Table 1.
Quality of assessment of the composite grafts
In progenitor cell targeted CNT-20 culture medium,
supplemented with 1% human blood type AB serum, bi-
opsies showed an average outgrowth of 14.4 mm ±
3.7 mm by day 14 (Figure 4). The cells displayed a
cobblestone epithelial phenotype when observed under
phase contrast microscopy with a clear leading edge
devoid of any cell debris. The grafts were assessed for
the presence of a high percentage of progenitor cells
using a panel of markers (Figure 5). The predominant
phenotype (>50%) consisted of small cells with highnuclear-cytoplasmic ratio, showed positive expression
for ABCG2, ΔNp63 and CK14 and negative expression
for CK3/12 and desmoglein 3, all of which is consistent
with a more immature progenitor phenotype. ABCG2
showed weak cytoplasmic and strong nuclear expression
co-localizing with the transcription factor ΔNp63. VEGF-
R1 and VEGF-R3 showed weak cytoplasmic staining (not
all data is shown).
Postoperative outcomes
The transplant recipients were followed up for a mean
of 22 months (range 4–43 months). Overall, 12 of the 18
recipients were graded anatomically successful (Table 1),
resulting in a persistent continuous epithelial surface in
67% (95% CI:0.45 – 0.88). Representative images are dis-
played (Figure 6). Two of the 3 allogenic transplant re-
cipients were graded as successful and 10 of the 15
autologous cases were deemed anatomically successful.
A higher success rate was seen in women (p = 0.038)
and a lower rate of success was seen in chemical burns
(p = 0.013). Eight of the 12 patients were determined to
be functional successes. Over the entire cohort we did
not see a significant reduction in either pain or photo-
phobia in the patient group post stem cell grafting.
When we assessed the subgroup that achieved an ana-
tomical success, there was a significant but modest
improvement in visual acuity (p = 0.0289) with the exclu-
sion of one outlier (Figure 7A). The outlying patient had
a partial deficiency (Figure 7B) and the significant visual
improvement was more attributed to the minimal in-
volvement of the central cornea when compared with all
of the other cases. When the group was assessed as a
whole there was no significant increase in visual acuity
(P = 0.065) (Figure 7B). In the success subgroup, there was
a significant improvement in pain (p = 0.040) (Figure 8A)
though there was no significant difference in photophobia
(p = 0.029) (Figure 8B). Analysis of the ocular surface
photographs showed that there was a significant reduc-
tion (p = 0.007) in the percentage area of corneal neo-
vascularization in the successful subgroup (Figure 8C),
which persisted in patients who underwent subsequent
PK (p = 0.01). There was no significant influence on
opacification after LSCT (p = 0.89) but there was a signifi-
cant improvement seen after PK (p = 0.029) (Figure 8D).
Seven patients in total received PKs, six to restore vision
and one as a treatment for corneal perforation. Of these
seven, the emergency graft was rejected and one of the six
grafts to improve visual acuity was rejected and opacified
(follow up range 7 – 36 months).
Anatomical failures
In the six cases of surgical failure, the graft failed to
adhere and integrate with the hosts for a number of
reasons. The first case (total limbal stem cell deficiency)
Figure 2 Limbal epithelial cells cultivated on amniotic membrane in progenitor cell CNT-20 versus SHEM medium. LECs grown in CNT20
and SHEM stained for the expression of Collagen IV and Integin alpha 6 (A), Laminin and Connexin 43 (B) and Collagen II and ΔNp63 (C).
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reconjunctivalization of the cornea. Case number four
had a period of initial integration followed by conjunc-
tival overgrowth and had coexisting glaucoma. The fifth
case had a stable enough surface to implant a PK but
failed shortly thereafter. Patient 8 had recurrent epithe-
lial defects and despite lubricants and a contact lens the
defect did not close. The patient was noncompliant with
clinic appointments thereafter. Patient number 10
showed conjunctival overgrowth but was incarcerated
after 19 months of follow up. Since regular clinic atten-
dances were not possible the patient was lost to furthertreatment. Patient 15 developed a perforation at the
graft-host junction of a prior PK three days after LSCT.
This was treated with an emergency PK, but in the
absence of limbal stem cells, the graft failed.
Discussion
In this study, we reported the results of a cultivated lim-
bal stem cell protocol in a prospective phase I/II non-
randomized clinical trial in 18 consecutive patients. The
earliest clinical trials reported a culture protocol that
included the use animal derived (xenogenic) products.
Subsequent clinical trials have improved the patient
Figure 3 Preoperative images. All three partial deficiency patients are shown (A-C) and three representative total deficiency patients (D-F).
Representative images of two patients with total limbal stem cell deficiency prior to (G, J) and following (H, K) limbal stem cell transplantation.
The same eyes following penetrating karatoplasty (I, L).
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protocol. There is still variability in patient selection,
culture techniques, donor materials and surgical tech-
nique across the reported studies and a widely accepted
optimized protocol has not yet been developed. The
presence of animal products such as mouse fibroblast
feeder layers, FBS and cholera toxins carry potential
health risks [22]. All of the bioengineered tissues pro-
duced using murine feeder cells are classified as xeno-
grafts by the US Food and Drug Administration (FDA)
[23] and may incorporate nonhuman proteins such as
sialic acids [24]. Animal products such as FBS have mul-
tiple constituents that vary in composition quality but
may also be contaminated by endotoxins, haemoglobin,
viruses, bacteria and prions.
In this clinical trial we aimed to optimize our ap-
proach by developing a standardized HAM preparation
under xeno-free and stabilized culture conditions togenerate the compostie grafts. We report that culturing
LECs with serum–free CNT-20 on HAMs was unsuc-
cessful, indicating that serum support is essential. We
therefore substituted human serum for FBS, which has
previously been shown to be successful in cultivating
limbal stem cell grafts on HAM [6,7,13,14]. Clinical
grade 1% human AB serum was an effective replacement
for the bovine serum. Lekhanont et al. have also de-
scribed a successful xeno-free technique of culturing
corneal epithelial cells [25]. The Epilife medium used in
this study, unlike CNT-20, is not specifically targeted to-
wards proliferation of corneal progenitors. The CNT-20
protocol described here shows a higher proportion of
progenitor cells with large nuclear to cytoplasmic ratios,
and higher expression of ΔNp63+ and ABCG2+ than
reported in the Epilife protocol. However these data are
largely qualitative and further studies using quantitative
analyses are warranted. We also reported a >8 mm
Table 1 Overview of patients enrolled within the clinical trial
Total LSCD
No. AGE SEX LSCD etiology Type Follow-up (months) VA before VA after Tx Post LEC TX Result
1 44 M Chemical burn allo* auto 41 CF (0.014) CF (0.014) PK Failed
2 45 F Chemical burn auto 43 HM (0.005) 0,05 - AS, FS
4 45 M Chemical burn auto 31 CF (0.014) <0,05 - Failed
5 6 M Chemical burn auto 31 HM (0.005) LP (0) PK Failed
6 27 M Aniridia allo** 27 0.053 0.1 PK AS, FS
7 70 F Corneal ulcer auto 25 LP (0) HM (0.005) PK AS, FS
8 29 M Chemical burn auto 25 <0,05 HM (0.005) - Failed
10 33 M Chemical burn auto 19 LP (0) LP (0) - Failed
11 63 M Iatrogenic auto 19 HM (0.005) HM (0.005) - AS
13 31 F Aniridia allo** 48 CF (0.014) 0.2 PK AS, FS
14 16 F Kniest syndrome auto 6 LP (0) HM (0.005) - AS
15 6 M Keratitis auto 5 LP (0) LP (0) - Failed
16 48 M Chemical burn auto 4 CF (0.014) 0.125 - AS, FS
17 79 M Trauma auto 4 CF (0.014) CF (0.014) - AS
18 42 F Viral keratitis auto 18 LP (0) HM (0.005) PK AS, FS
Partial LSCD
No. AGE SEX LSCD Etiology Type Follow-up (months) VA before VA after Tx Post LEC TX Result
3 57 F Iatrogenic auto 39 0.15 0,16 - AS, FS
9 44 F Keratitis, uveitis auto 24 CF (0.014) 0.15 PK AS, FS
12 47 M Trauma auto 18 0.2 0.9 - AS, FS
The table shows the subject code, age, sex, etiology of LCSD (Limbal Stem Cell Deficency), type of donor (allo* = allogenic cadaveric, allo** = from living related
donor), the follow-up, visual acuities pre and post op (LP = light perception, CF = counting fingers, HM = hand movements) surgical interventions following LEC TX
(Limbal epithelial cell transplant) particularly PK (penetrating keratoplasty) procedures and the vision at most recent follow-up (AS = anatomical success,
FS = functional success).
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in culture on standardized HAMs by day 14, compared
with 70% outgrowth with Epilife [25].
The cell substrates are also known to play an import-
ant role in maintaining the contact microenvironment
necessary for regulating cell behavior in vitro [26]. As
such, we standardized our HAM to provide fixed, smooth
membranes [15]. Amniotic membrane stabilization tech-
niques have been described [27] but we customized theFigure 4 Composite graft generation. Phase contrast microscopy of a lim
outgrowth after the 14-day culture protocol (B) (n = 18).technique with a view to simplifying both the culture and
surgical implantation protocols. Once the membrane is
locked and the limbal explant seeded there is no need to
touch or move the membrane. During surgery the com-
posite graft can be sited and cut free with minimal ma-
nipulation reducing mechanical stress on the cultured
cells and folds that predispose to primary failure of epithe-
lialization [13]. In our centre only the first patient of the
cohort experienced primary failure which may have beenbal biopsy and proliferating cells (A) (magnification × 200) and the
Figure 5 Immunofluorescence microscopy of composite grafts. Cells were stained for the presence of CK14 (A), CK3/12 (D), ΔNp63 (B, E).
(C) and (F) are composites of (A, B) and (D, E) respectively. Negative controls are shown in (G), (H) and (I).
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The five other failures occurred after an initial period of
integration. Suture techniques may influence graft survival
and promote vasculariszation [28-30]. In this protocol we
reduce the influence of sutures by securing the composite
graft with tissue fibrin glue and a temporary HAM patch.
The patch, providing a reservoir of TGF-beta [19] is
sutured under the free edge of the conjunctiva rather than
to the cornea and any conjunctival overgrowth is dis-
carded along with the patch at week one.Figure 6 Clinical images. Representative images of patients that achieved aAnatomical success consistent with restoration of the
corneal epithelium was seen in 67% of participants.
While eighteen patients may represent a small popula-
tion, the success rate is similar to that previously
described [31]. Higher rates of rejection have been re-
ported with allogenic transplantation [8] though this was
not seen replicated in this study. Validation over a larger
group would be required to substantiate this. Patients
with chemical burns featured strongly in the failed graft
cohort which is contrary to what has been reported innatomical success; pre op (A +D), post LSCT (B + E) and post PK (C + F).
Figure 7 Visual acuity. Post-operative visual acuity outcomes in patients that achieved anatomical success (A) and for the total cohort (B) (* = p < 0.05).
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are at higher risk of graft failure [27], which may be the
case in this cohort. Currently no standardized methods
exist for detecting chronic or subclinical inflammation
and assessment is usually made at the slit lamp on basis
of vessel dilation. Further research into developing tools
to detect inflammatory cytokines in tear samples may
aid in determining inflammatory status of the eye prior
to transplantation thereby improving overall outcome.
Three cases of partial limbal stem cell deficiency were
also included in the study as all three were persistent
despite repeated surgical debridement and reconstruction.
All three cases were found to achieve both anatomical and
functional improvements, although including the partial
cases increases the heterogeneity within the group. One-Figure 8 Additional post-operative outcomes. Post-operative outcomes
vascularization (C) and opacity (D), (* = p < 0.05, **p < 0.01).year post successful transplant, patients were offered a
penetrating keratoplasty, which was performed in six cases
for the purposes of visual improvement. In addition to the
improvement in visual acuity, there was a significant
decrease in corneal neovascularization seen. Impression
cytology was only performed preoperatively to aid in diag-
nosis. Since cell pick-up was low and the procedure risked
disrupting the transplanted epithelium, the test was not
performed post operatively.
Objective assessments of corneal opacification have
been developed [32-34] but these cannot be applied to
LSCD cases as the backscatter is too high and renders
the results unusable. The technique of opacity assess-
ment here is based on analysis of slit lamp photographs,
while not optimal, is a quantitative value of corneal hazein the anatomically successful groups: pain (A), photophobia (B),
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http://www.translational-medicine.com/content/12/1/58that can be applied to these patients. At the time of sur-
gery, the composite grafts contained both the cultured
cells and the segment of the original limbal biopsy. This
was based on the assumption that including the original
biopsy in the graft would provide an additional benefit
of the limbal niche. There was a concern however that
the addition of this tissue could increase opacification.
This was not observed and there was no significant
effect of the graft procedure on central corneal opacity.
Visual acuity improved after successful graft integration
so this may indicate a reduction in opacity that is too
subtle for this measurement technique to detect. Opaci-
fication did significantly improve after a PK procedure
but the differences in clarity were great and relatively
simple for the technique to detect. We conclude that
this method is insufficiently sensitive to detect smaller
changes in opacity and further work is required to
develop a practical means of objectively determining
corneal haze in this cohort.
In long-term limbal stem cell insufficiency, the chronic
inflammatory process results in scarring that penetrates
deep into the cornea. The replacement of the epithelial
surface therefore has only a modest effect on vision.
Limbal stem cell grafting therapy in these patients
should not be considered sight-restorative. The aim is to
provide a more normal epithelial surface and a safer plat-
form on which to perform a PK that would improve vision.
Conclusion
This study reports the results of a clinical trial with
focus on building on the work of its predecessors. From
biopsy to implantation we aimed to optimize the tech-
nique to remove the xenogenic components in culture,
promote an undifferentiated morphology with CNT20
medium, standardize and stabilize the amniotic mem-
branes with rings, simplify surgery and reduce any ma-
nipulation of the composite graft. We report the
objective (visual acuity, slit lamp examination of the epi-
thelium) and subjective outcomes (photophobia, pain) in
our cohort and augment this with an objective assess-
ment of area of neovascularization and opacification.
We also provide a description outlining the features of
the clinical failures. As the technique of cultured limbal
stem cell grafting matures and is performed more
widely, further optimization studies will be required in
the future to achieve the perfect protocol for the best
results in these complex patients.
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